Recently, promising strategies have been proposed, relying on the CRISPR-CAS9 approach, novel nano-based drug delivery systems, which increased the detection of HIF factors at tumor sites, and HIF-1α-specific siRNA-loaded nanoparticles, which inhibit tumor metastasis in pancreatic models, allowing a better and more specific tumor delivery [40,44,45]. This evidence concerns the gene HIF1A and neoplasm.